Reversal of EMT by etoposide treatment downregulates PD-L1 and sensitizes cancer cells to T-cell immunoglobulin mucin-3 (Tim-3) immune checkpoint blockade (ICB) therapy in mouse models of breast and colon cancers [47] (Fig. 2). This evidence concerns the gene CD274 and cancer.